1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

18 May 2024
Admin
News Article

Nona Biosciences Does Agreement with AstraZeneca for Monoclonal Antibody

Nona Biosciences inks license and option agreement with AstraZeneca for monoclonal antibody to be developed into novel tumour targeted therapies

Overview

Nona Biosciences, a global biotechnology company providing a total solution from “Idea to IND” (I to ITM), ranging from target validation and antibody discovery through preclinical research, announced that it has entered into a license agreement with AstraZeneca for preclinical monoclonal antibodies that will be used to create targeted therapies in oncology.

Terms of the Sgreement

Under the terms of the agreement, Nona Biosciences shall receive US$ 19 million upon completion of the transaction.
Nona is eligible to receive an additional US$ 10 million in potential near-term milestone payments and up to US$ 575 million upon achieving specified development, regulatory, and commercial milestones, as well as tiered royalty payments on net sales.
In addition, Nona is eligible to receive payments for the option programs should AstraZeneca exercise these options.

Words from MD: Nona Biosciences

"We are delighted to announce this agreement with AstraZeneca, global leaders in developing tumour targeted therapies, to maximize the potential of our novel antibodies,” said Jingsong Wang, M.D., Ph.D., chairman of Nona Biosciences.
“This agreement further validates our leading antibody discovery platform, and we look forward to seeing our antibodies developed into potential new medicines for cancer patients.”

From AstraZeneca

Puja Sapra, senior vice president, tumour targeted delivery, oncology R&D, AstraZeneca, said: “The global license agreement with Nona Biosciences is an exciting opportunity to further develop these antibodies derived from Nona’s innovative biologics discovery engine into novel tumour targeted therapies using AstraZeneca’s industry-leading capabilities.”

Nona Biosciences

Nona Biosciences (a wholly-owned subsidiary of HBM Holdings Limited) is a global biotechnology company committed to cutting-edge technology innovation and provides a total solution from “Idea to IND” (I to ITM), ranging from target validation and antibody discovery through preclinical research.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!